News
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...
Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been ...
South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running ...
South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.
5d
Yonhap News Agency on MSNSK bioscience wins patent dispute against Pfizer over pneumococcal vaccineSEOUL, May 21 (Yonhap) -- SK bioscience Co., a biotech arm of South Korea's SK Group, said Wednesday it has won a patent ...
The introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in the U.S. in 2000 was a welcome addition to our preventive armamentarium; however, questions remain regarding the degree ...
Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results